BCWORLD PHARM. Co., Ltd.

KOSDAQ:A200780 Stock Report

Market Cap: ₩31.1b

BCWORLD PHARM Past Earnings Performance

Past criteria checks 0/6

BCWORLD PHARM's earnings have been declining at an average annual rate of -9%, while the Pharmaceuticals industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 4.9% per year.

Key information

-8.96%

Earnings growth rate

-11.34%

EPS growth rate

Pharmaceuticals Industry Growth11.32%
Revenue growth rate4.95%
Return on equity-1.77%
Net Margin-3.61%
Last Earnings Update30 Jun 2026

Recent past performance updates

Analysis Article • Mar 18

Investors Shouldn't Be Too Comfortable With BCWORLD PHARM's (KOSDAQ:200780) Earnings

Despite posting some strong earnings, the market for BCWORLD PHARM. Co., Ltd.'s ( KOSDAQ:200780 ) stock hasn't moved...

Recent updates

Analysis Article • Dec 12

BCWORLD PHARM. Co., Ltd.'s (KOSDAQ:200780) Popularity With Investors Is Under Threat From Overpricing

There wouldn't be many who think BCWORLD PHARM. Co., Ltd.'s ( KOSDAQ:200780 ) price-to-sales (or "P/S") ratio of 0.6x...
Analysis Article • Jan 03

Revenues Not Telling The Story For BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780) After Shares Rise 30%

BCWORLD PHARM. Co., Ltd. ( KOSDAQ:200780 ) shareholders would be excited to see that the share price has had a great...
Analysis Article • Dec 04

Does BCWORLD PHARM (KOSDAQ:200780) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Mar 18

Investors Shouldn't Be Too Comfortable With BCWORLD PHARM's (KOSDAQ:200780) Earnings

Despite posting some strong earnings, the market for BCWORLD PHARM. Co., Ltd.'s ( KOSDAQ:200780 ) stock hasn't moved...
Analysis Article • Mar 01

BCWORLD PHARM (KOSDAQ:200780) Seems To Be Using A Lot Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Feb 09

Does The Market Have A Low Tolerance For BCWORLD PHARM. Co., Ltd.'s (KOSDAQ:200780) Mixed Fundamentals?

With its stock down 18% over the past month, it is easy to disregard BCWORLD PHARM (KOSDAQ:200780). We, however decided...
Analysis Article • Jan 25

Is BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780) A Good Dividend Stock?

Could BCWORLD PHARM. Co., Ltd. ( KOSDAQ:200780 ) be an attractive dividend share to own for the long haul? Investors...
Analysis Article • Jan 11

If You Had Bought BCWorld Pharm (KOSDAQ:200780) Stock A Year Ago, You Could Pocket A 75% Gain Today

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can...
Analysis Article • Dec 26

Do Insiders Own Lots Of Shares In BCWorld Pharm Co., Ltd. (KOSDAQ:200780)?

Every investor in BCWorld Pharm Co., Ltd. ( KOSDAQ:200780 ) should be aware of the most powerful shareholder groups...
Analysis Article • Dec 08

Are BCWorld Pharm's (KOSDAQ:200780) Statutory Earnings A Good Guide To Its Underlying Profitability?

Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
Analysis Article • Nov 18

Is BCWorld Pharm (KOSDAQ:200780) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Revenue & Expenses Breakdown

How BCWORLD PHARM makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A200780 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2680,328-2,89717,0459,390
31 Mar 2679,812-2,51017,1479,028
31 Dec 2575,800-4,89718,3578,990
30 Sep 2577,044-3,76517,7398,666
30 Jun 2575,316-3,74317,1527,969
31 Mar 2574,334-4,93716,6227,628
31 Dec 2474,814-4,43316,0017,779
30 Sep 2472,884-8,07515,9657,690
30 Jun 2472,959-6,89716,2627,381
31 Mar 2472,19585916,3216,757
31 Dec 2375,1112,63416,3506,141
30 Sep 2376,0566,24023,560-1,616
30 Jun 2376,2135,65123,202-1,308
31 Mar 2376,04048122,746306
31 Dec 2272,70328121,296771
30 Sep 2268,91825512,7439,180
30 Jun 2266,489-64412,3599,454
31 Mar 2263,383-2,94411,9169,135
31 Dec 2162,079-1,84311,7129,298
30 Sep 2159,217-8,50812,10310,011
30 Jun 2157,763-6,03211,43410,976
31 Mar 2157,071-1,95610,42711,225
31 Dec 2057,030-1,58010,91710,951
30 Sep 2056,434-2,45010,39510,761
30 Jun 2056,034-1,39210,2139,667
31 Mar 2054,135-1,97210,6178,616
31 Dec 1951,497-1,5539,7608,444
30 Sep 1951,4405,0119,3087,393
30 Jun 1952,4924,7619,0577,324
31 Mar 1953,8235,0248,9837,500
31 Dec 1854,7924,9938,6267,241
30 Sep 1854,7227,7778,4807,211
30 Jun 1853,0448,1248,3326,896
31 Mar 1851,0088,0008,3276,464
31 Dec 1750,2078,0838,3486,650
31 Dec 1645,6586,4759,1206,557

Quality Earnings: A200780 is currently unprofitable.

Growing Profit Margin: A200780 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A200780 is unprofitable, and losses have increased over the past 5 years at a rate of 9% per year.

Accelerating Growth: Unable to compare A200780's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A200780 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (47.8%).

Return on Equity

High ROE: A200780 has a negative Return on Equity (-1.77%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 00:25
End of Day Share Price 2026/09/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BCWORLD PHARM. Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.